(NYSE: ANVS) (Annovis or the Company), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimers disease (AD) and Parkinsons disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity) in a mouse model of Alzheimers disease
To find out how much youll pay for Ozempic, review your plan's drug formulary
The above doses are average recommendations
Is it safe to use PT-141 with other medications
Crack PJ, Taylor JM, Flentjar NJ, de Haan J, Hertzog P, Iannello RC et al
Join the hundreds of thousands who trust AgelessRx to guide their path to healthier aging